Olubukola Ayodele, Consultant Medical Oncologist at University Hospitals of Leicester Cancer Research Centre, shared a post on LinkedIn:

“I had the pleasure of meeting with Daniel Heng, the creator of the IMDC prognostic risk criteria for aRCC. While this criteria has traditionally been used to determine patient treatment, we are now recognising that a patient’s biology plays a crucial role in treatment decisions. Pathologists cannot simply provide histological reports as renal cell carcinoma or clear/non-clear cell RCC. Instead, we need to identify the molecular subtype, which serves as an important prognostic and predictive indicator of response to systemic therapy, superseding the significance of the IMDC risk.”

Source: Olubukola Ayodele/LinkedIn

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”